NATCO Pharma Limited has scheduled a meeting of its Board of Directors for May 29, 2026. The primary agenda is to consider and approve the company’s audited financial results for the quarter and fiscal year ending March 31, 2026. In conjunction with this meeting, the company has implemented a temporary suspension of trading activities for designated persons to ensure compliance with internal governance protocols.
Upcoming Board Meeting
The Board of Directors of NATCO Pharma Limited is set to convene on Friday, May 29, 2026. During this session, the leadership team will review and approve the financial performance of the company for both the final quarter and the full fiscal year concluded on March 31, 2026.
Trading Window Closure
To maintain transparency and adhere to governance standards, the company has announced the closure of its trading window. This restriction, which applies to employees, connected persons, and their immediate relatives, takes effect from May 19, 2026. The window will remain closed until 48 hours following the official publication of the financial results. This measure is standard practice to prevent unauthorized trading while sensitive financial data is being finalized.
Source: BSE
